121 related articles for article (PubMed ID: 10465068)
1. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.
Goebel FD; Mannhalter JW; Belshe RB; Eibl MM; Grob PJ; de Gruttola V; Griffiths PD; Erfle V; Kunschak M; Engl W
AIDS; 1999 Aug; 13(12):1461-8. PubMed ID: 10465068
[TBL] [Abstract][Full Text] [Related]
2. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
3. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
4. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group.
Sandström E; Wahren B
Lancet; 1999 May; 353(9166):1735-42. PubMed ID: 10347985
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
7. Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization.
Gudmundsdotter L; Boström AC; Burton C; Rosignoli G; Sandström E; Hejdeman B; Wahren B; Imami N; Gotch F
Vaccine; 2008 Sep; 26(40):5107-10. PubMed ID: 18455841
[TBL] [Abstract][Full Text] [Related]
8. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137).
Valentine FT; Kundu S; Haslett PA; Katzenstein D; Beckett L; Spino C; Borucki M; Vasquez M; Smith G; Korvick J; Kagan J; Merigan TC
J Infect Dis; 1996 Jun; 173(6):1336-46. PubMed ID: 8648205
[TBL] [Abstract][Full Text] [Related]
11. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
Pontesilli O; Guerra EC; Ammassari A; Tomino C; Carlesimo M; Antinori A; Tamburrini E; Prozzo A; Seeber AC; Vella S; Ortona L; Aiuti F
AIDS; 1998 Mar; 12(5):473-80. PubMed ID: 9543445
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children. National Institutes of Health-sponsored Pediatric AIDS Clinical Trials Group (ACTG-218).
Lambert JS; McNamara J; Katz SL; Fenton T; Kang M; VanCott TC; Livingston R; Hawkins E; Moye J; Borkowsky W; Johnson D; Yogev R; Duliege AM; Francis D; Gershon A; Wara D; Martin N; Levin M; McSherry G; Smith G
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):451-61. PubMed ID: 9859958
[TBL] [Abstract][Full Text] [Related]
13. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
[TBL] [Abstract][Full Text] [Related]
15. Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; McElrath MJ; Matthews TJ; Hsieh RH; Belshe RB; Corey L; Frey SE; Kennedy DJ; Walker MC; Eibl MM
Vaccine; 1998 Mar; 16(5):493-506. PubMed ID: 9491504
[TBL] [Abstract][Full Text] [Related]
16. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
Gorse GJ; Simionescu RE; Patel GB
Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
[TBL] [Abstract][Full Text] [Related]
17. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
18. Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen.
Katzenstein DA; Kundu S; Spritzler J; Smoller BR; Haszlett P; Valentine F; Merigan TC
J Acquir Immune Defic Syndr; 1999 Dec; 22(4):341-7. PubMed ID: 10634195
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. Community HIV Research Network Investigators.
Kelleher AD; Roggensack M; Jaramillo AB; Smith DE; Walker A; Gow I; McMurchie M; Harris J; Patou G; Cooper DA
AIDS; 1998 Jan; 12(2):175-82. PubMed ID: 9468366
[TBL] [Abstract][Full Text] [Related]
20. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment.
Bratt G; Eriksson LE; Sandström E; Gilljam G; Hinkula J; Albert J; Redfield R; Wahren B
Int J STD AIDS; 1999 Aug; 10(8):514-21. PubMed ID: 10471100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
